# Faraday Future Intelligent Electric Inc.: financial statements, quarterly

FFAI · Nasdaq · CIK 1805521 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ffai.md) · [Financials](/companies/ffai/financials.md) · [Filings](/companies/ffai/filings.md) · [Insiders](/companies/ffai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ffai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.6](/filings/0001628280-24-046478.md) | [0.2 d](/filings/0001628280-25-015548.md) | [0.0](/filings/0001628280-25-024006.md) | [0.3](/filings/0001628280-25-040825.md) | [0.0](/filings/0001628280-25-053577.md) | [0.2 d](/filings/0001628280-26-022509.md) | [0.3](/filings/0001628280-26-035138.md) | [0.1](/filings/0001628280-26-056740.md) | [0.0](/filings/0001628280-25-053577.md) | [0.1 d](/filings/0001628280-26-022509.md) | [0.5](/filings/0001628280-26-035138.md) | [0.8](/filings/0001628280-26-056740.md) |
| Gross profit | $m | [(15.6)](/filings/0001628280-24-046478.md) | [(19.6) d](/filings/0001628280-25-015548.md) | [(20.7)](/filings/0001628280-25-024006.md) | [(20.7)](/filings/0001628280-25-040825.md) | [(21.4)](/filings/0001628280-25-053577.md) | [(20.7) d](/filings/0001628280-26-022509.md) | [(21.1)](/filings/0001628280-26-035138.md) | [(26.9)](/filings/0001628280-26-056740.md) | [(34.2)](/filings/0001628280-25-053577.md) | [(15.6) d](/filings/0001628280-26-022509.md) | [(11.4)](/filings/0001628280-26-035138.md) | [(10.7)](/filings/0001628280-26-056740.md) |
| Research and development | $m | [21.6](/filings/0001628280-24-046478.md) | [27.4 d](/filings/0001628280-25-015548.md) | [6.7](/filings/0001628280-25-024006.md) | [3.3](/filings/0001628280-25-040825.md) | [5.2](/filings/0001628280-25-053577.md) | [10.0 d](/filings/0001628280-26-022509.md) | [6.4](/filings/0001628280-26-035138.md) | [5.0](/filings/0001628280-26-056740.md) | [6.6](/filings/0001628280-25-053577.md) | [(1.5) d](/filings/0001628280-26-022509.md) | [7.0](/filings/0001628280-26-035138.md) | [4.1](/filings/0001628280-26-056740.md) |
| Operating income | $m | [(66.4)](/filings/0001628280-24-046478.md) | [(67.8) d](/filings/0001628280-25-015548.md) | [(43.6)](/filings/0001628280-25-024006.md) | [(50.6)](/filings/0001628280-25-040825.md) | [(25.2)](/filings/0001628280-25-053577.md) | [(30.3) d](/filings/0001628280-26-022509.md) | [(43.8)](/filings/0001628280-26-035138.md) | [(48.1)](/filings/0001628280-26-056740.md) | [(207)](/filings/0001628280-25-053577.md) | [(32.3) d](/filings/0001628280-26-022509.md) | [(35.9)](/filings/0001628280-26-035138.md) | [(34.8)](/filings/0001628280-26-056740.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-046478.md) | [0.1 d](/filings/0001628280-25-015548.md) | [0.0](/filings/0001628280-25-024006.md) | [0.0](/filings/0001628280-25-040825.md) | [(0.0)](/filings/0001628280-25-053577.md) | [(0.3) d](/filings/0001628280-26-022509.md) | [0.0](/filings/0001628280-26-035138.md) | [0.0](/filings/0001628280-26-056740.md) | [0.0](/filings/0001628280-25-053577.md) | [0.0 d](/filings/0001628280-26-022509.md) | [0.0](/filings/0001628280-26-035138.md) | [(0.9)](/filings/0001628280-26-056740.md) |
| Net income | $m | [(78.0)](/filings/0001628280-24-046478.md) | [(83.8) d](/filings/0001628280-25-015548.md) | [(48.2)](/filings/0001628280-25-024006.md) | [(109)](/filings/0001628280-25-040825.md) | [(77.7)](/filings/0001628280-25-053577.md) | [(121) d](/filings/0001628280-26-022509.md) | [(10.3)](/filings/0001628280-26-035138.md) | [(125)](/filings/0001628280-26-056740.md) | [(222)](/filings/0001628280-25-053577.md) | [(33.6) d](/filings/0001628280-26-022509.md) | [(38.9)](/filings/0001628280-26-035138.md) | [(36.0)](/filings/0001628280-26-056740.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.7](/filings/0001628280-24-046478.md) | [1.9](/filings/0001628280-25-015548.md) | [0.4](/filings/0001628280-25-024006.md) | [0.8](/filings/0001628280-25-040825.md) | [7.3](/filings/0001628280-25-053577.md) | [7.1](/filings/0001628280-26-022509.md) | [9.5](/filings/0001628280-26-035138.md) | [13.2](/filings/0001628280-26-056740.md) | [62.9](/filings/0001628280-25-053577.md) | [34.9](/filings/0001628280-26-056740.md) | [12.2](/filings/0001628280-26-035138.md) | [11.2](/filings/0001628280-26-056740.md) |
| Current assets | $m | [127](/filings/0001628280-23-038646.md) | [91.4](/filings/0001628280-25-015548.md) | [82.7](/filings/0001628280-24-033559.md) | [70.1](/filings/0001628280-24-037267.md) | [79.7](/filings/0001628280-24-046478.md) | [71.9](/filings/0001628280-26-022509.md) | [76.5](/filings/0001628280-25-024006.md) | [76.6](/filings/0001628280-25-040825.md) | [90.0](/filings/0001628280-25-053577.md) | [68.5](/filings/0001628280-26-056740.md) | [41.9](/filings/0001628280-26-035138.md) | [52.1](/filings/0001628280-26-056740.md) |
| Total assets | $m | [580](/filings/0001628280-23-038646.md) | [531](/filings/0001628280-25-015548.md) | [500](/filings/0001628280-24-033559.md) | [458](/filings/0001628280-24-037267.md) | [449](/filings/0001628280-24-046478.md) | [425](/filings/0001628280-26-022509.md) | [411](/filings/0001628280-25-024006.md) | [400](/filings/0001628280-25-040825.md) | [316](/filings/0001628280-25-053577.md) | [278](/filings/0001628280-26-056740.md) | [250](/filings/0001628280-26-035138.md) | [280](/filings/0001628280-26-056740.md) |
| Current liabilities | $m | [191](/filings/0001628280-23-038646.md) | [261](/filings/0001628280-25-015548.md) | [257](/filings/0001628280-24-033559.md) | [268](/filings/0001628280-24-037267.md) | [248](/filings/0001628280-24-046478.md) | [193](/filings/0001628280-26-022509.md) | [189](/filings/0001628280-25-024006.md) | [223](/filings/0001628280-25-040825.md) | [211](/filings/0001628280-25-053577.md) | [148](/filings/0001628280-26-056740.md) | [118](/filings/0001628280-26-035138.md) | [136](/filings/0001628280-26-056740.md) |
| Total liabilities | $m | [318](/filings/0001628280-23-038646.md) | [302](/filings/0001628280-25-015548.md) | [298](/filings/0001628280-24-033559.md) | [309](/filings/0001628280-24-037267.md) | [292](/filings/0001628280-24-046478.md) | [310](/filings/0001628280-26-022509.md) | [271](/filings/0001628280-25-024006.md) | [340](/filings/0001628280-25-040825.md) | [355](/filings/0001628280-25-053577.md) | [270](/filings/0001628280-26-056740.md) | [231](/filings/0001628280-26-035138.md) | [278](/filings/0001628280-26-056740.md) |
| Shareholders' equity | $m | [262](/filings/0001628280-24-046478.md) | [228](/filings/0001628280-25-040825.md) | [202](/filings/0001628280-25-040825.md) | [149](/filings/0001628280-25-040825.md) | [157](/filings/0001628280-24-046478.md) | [115](/filings/0001628280-26-022509.md) | [140](/filings/0001628280-25-040825.md) | [59.9](/filings/0001628280-25-040825.md) | [(77.7)](/filings/0001628280-25-053577.md) | [(27.3)](/filings/0001628280-26-056740.md) | [(12.4)](/filings/0001628280-26-035138.md) | [(27.3)](/filings/0001628280-26-056740.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(79.7) d](/filings/0001628280-24-046478.md) | [(37.8) d](/filings/0001628280-25-015548.md) | [(14.7)](/filings/0001628280-25-024006.md) | [(14.4) d](/filings/0001628280-25-040825.md) | [(22.7) d](/filings/0001628280-25-053577.md) | [(18.4) d](/filings/0001628280-26-022509.md) | [(20.3)](/filings/0001628280-26-035138.md) | [(23.3) d](/filings/0001628280-26-056740.md) | [(35.6) d](/filings/0001628280-25-053577.md) | [(2.1)](/filings/0001628280-26-022509.md) | [(31.5)](/filings/0001628280-26-035138.md) | [(25.1) d](/filings/0001628280-26-056740.md) |
| Capital expenditure | $m | [(15.0) d](/filings/0001628280-24-046478.md) | [20.3 d](/filings/0001628280-25-015548.md) | [0.1](/filings/0001628280-25-024006.md) | [0.3 d](/filings/0001628280-25-040825.md) | [0.3 d](/filings/0001628280-25-053577.md) | [6.9 d](/filings/0001628280-26-022509.md) | [1.6](/filings/0001628280-26-035138.md) | [3.4 d](/filings/0001628280-26-056740.md) | [1.5 d](/filings/0001628280-25-053577.md) | [1.1 d](/filings/0001628280-26-022509.md) | [0.2](/filings/0001628280-26-035138.md) | [1.4 d](/filings/0001628280-26-056740.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001628280-24-025420.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q1 FY2023 (2023-03-31) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [322](/filings/0001628280-23-017931.md) | [989](/filings/0001628280-23-017931.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,516,511 at 2021-08-13, from the cover of the [10-Q filed 2021-08-13](/filings/0001213900-21-042428.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.